Loading...

Cardiovascular Systems, Inc.

CSII•NASDAQ
Healthcare
Medical - Devices
$20.00
$0.03(0.15%)

Cardiovascular Systems, Inc. (CSII) Stock Overview

Explore Cardiovascular Systems, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap844M
P/E Ratio-21.24
EPS (TTM)$-0.96
ROE-0.14%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$8.19

CSII Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cardiovascular Systems, Inc. (CSII) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $8.19.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -21.24 and a market capitalization of 844M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CSIIStats details for CSII are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CSIIAnalyst Recommendations details for CSII are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.

CEO

Scott Raymond Ward MS

Employees

725

Headquarters

1225 Old Highway 8 Northwest, Saint Paul, MN

Founded

2006

Frequently Asked Questions

;